Guest Editorial Commentary on the Findings of the GLAGOV Randomized Clinical Trial
US Cardiology Review · 2017
DOI: 10.15420/usc.11.1.ge ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift US Cardiology Review, 2017. Verfasst von Jakub Podolec und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Evolocumab – a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) – significantly reduces low-density lipoprotein cholesterol levels. This agent has been tested in a series of clinical trials, one of which is discussed here: the GLAGOV study. Statintreated patients with coronary disease were treated with evolocumab or placebo with the result that patients in the evolocumab group low-density lipoprotein cholesterol (LDL-C) levels were significantly lower than the placebo group. Athersclerotic plaque regression was noticed in greater number of patients treated with evolocumab compared with placebo (64.3% versus 47.3%). While we await results from large outcome trials on PCSK9 inhibitors, the GLAGOV trial provides interesting findings of clinical advantages that may extend to LDL-C levels as low as 20 mg/dl.
Zitieren
APA
Podolec, J., & Niewiara, L. (2017). Guest Editorial Commentary on the Findings of the GLAGOV Randomized Clinical Trial. US Cardiology Review. https://doi.org/10.15420/usc.11.1.ge
Vancouver
Podolec J, Niewiara L. Guest Editorial Commentary on the Findings of the GLAGOV Randomized Clinical Trial. US Cardiology Review. 2017. doi:10.15420/usc.11.1.ge
BibTeX
@article{Podolec2017,
author = {Podolec, Jakub and Niewiara, Lukasz},
title = {Guest Editorial Commentary on the Findings of the GLAGOV Randomized Clinical Trial},
journal = {US Cardiology Review},
year = {2017},
doi = {10.15420/usc.11.1.ge}
}
EUVIMED